Rossello, XavierPiñero, AntonioFernandez-Jimenez, RodrigoSanchez-Gonzalez, JavierPizarro, GonzaloGalan-Arriola, CarlosLobo-Gonzalez, ManuelVilchez, Jean PaulGarcia-Prieto, JaimeGarcia-Ruiz, Jose MGarcia-Alvarez, AnaSanz-Rosa, DavidIbáñez, Borja2020-04-132020-04-132018-08J Cardiovasc Transl Res. 2018; 11(4):310-3181937-5387http://hdl.handle.net/20.500.12105/9506The administration of the selective β3 adrenergic receptor (β3AR) agonist BRL-37344 protects from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits its translatability. We tested the cardioprotective effect of mirabegron, the first-in-class β3AR agonist approved for human use. A dose-response study was conducted in 6 pigs to select the highest intravenous dose of mirabegron without significant detrimental hemodynamic effect. Subsequently, closed chest anterior myocardial infarction (45 min ischemia followed by reperfusion) was performed in 26 pigs which randomly received either mirabegron (10 μg/kg) or placebo 5 min before reperfusion. Day-7 cardiac magnetic resonance (CMR) showed no differences in infarct size (35.0 ± 2.0% of left ventricle (LV) vs. 35.9 ± 2.4% in mirabegron and placebo respectively, p = 0.782) or LV ejection fraction (36.3 ± 1.1 vs. 34.6 ± 1.9%, p = 0.430). Consistent results were obtained on day-45 CMR. In conclusion, the intravenous administration of the clinically available selective β3AR agonist mirabegron does not reduce infarct size in a swine model of IRI.engAMhttp://creativecommons.org/licenses/by-nc-nd/4.0/Acute myocardial infarctionCardioprotectionIschemia/reperfusion injuryMirabegronTranslational modelsβ3 adrenergic receptorAcetanilidesAdrenergic beta-3 Receptor AgonistsAnimalsDisease Models, AnimalMagnetic Resonance Imaging, CineMaleMyocardial InfarctionMyocardial Reperfusion InjuryMyocardiumRandom AllocationSwineThiazolesVentricular Function, LeftVentricular RemodelingAttribution-NonCommercial-NoDerivatives 4.0 Internacional30073540114310-31810.1007/s12265-018-9819-81937-5395Journal of cardiovascular translational researchopen access